Endo Recalls 16 Lots of Clonazepam Due to Mislabeling
A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.
Endo USA is expanding its previously announced recall of Clonazepam Orally Disintegrating Tablets because of carton strength mislabeling. The lots being recalled may contain cartons that show the product strength as 0.125 mg and not the correct stength of 0.25 mg.
The company said in a news release the recall is related to an error by a third-party packager. However, the company says the blister strips and tablets inside the product pack reflect the correct strength of 0.25 mg.
To date, Endo has not received any reports of adverse events associated with this product recall.
Clonazepam is a benzodiazepine used to treat patients with panic disorder and some types of epilepsy. Patients who take more than the recommended dose can experience sedation, confusion, dizziness, diminished reflexes, ataxia, and hypotonia.
A list of the lot and NDC numbers involved in this recall is located here.
In July 2024, Endo had recalled one lot because of a mislabeled carton.
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
